Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study

INTRODUCTION: Turoctocog alfa (NovoEight(®)) is a B‐domain‐truncated recombinant factor VIII (FVIII) approved for patients with haemophilia A. AIM: To investigate the long‐term safety and efficacy of turoctocog alfa in routine clinical practice. METHODS: Guardian 5 was a prospective, multinational,...

Descripción completa

Detalles Bibliográficos
Autores principales: Escuriola Ettingshausen, Carmen, Katsarou, Olga, Kotnik, Barbara Faganel, Borel Derlon, Annie, Schwarz, Rudolf, Ypma, Paula F., Matytsina, Irina, Dey, Sohan, Schutgens, Roger E. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298792/
https://www.ncbi.nlm.nih.gov/pubmed/34791736
http://dx.doi.org/10.1111/hae.14454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298792/
https://www.ncbi.nlm.nih.gov/pubmed/34791736
http://dx.doi.org/10.1111/hae.14454

Ejemplares similares